Bengaluru-based startup Healthify is leading India’s shift toward medically-assisted weight loss using GLP-1 drugs like Ozempic and Mounjaro. These diabetes medications have gained popularity worldwide for their strong weight loss effects.
Healthify recently launched HealthifyRx, a program combining these drugs with nutrition, exercise, and lifestyle coaching. The startup plans to offer this service in both India and the US.
Ozempic (semaglutide) and Mounjaro (tirzepatide) target the GLP-1 hormone, which controls blood sugar and appetite. By stimulating insulin and suppressing appetite, these drugs help lower blood sugar and promote weight loss. Originally available mostly to wealthy patients, they are expected to become widely accessible in India as patents expire.
The Indian anti-obesity drug market could reach \$100 billion by 2030. Studies estimate that by 2050, over 450 million Indians will be overweight or obese, making this a huge opportunity for drug makers and healthtech companies.
Alongside Healthify, major Indian pharma companies like Sun Pharma, Cipla, and Dr. Reddy’s are preparing to manufacture these drugs locally by 2026.
Healthify’s CEO Tushar Vashisht compares their program to riding an electric bike — the drug accelerates progress, but patients still need to pedal by adopting healthy habits. The program includes personalized meal plans, strength training, and careful dosage management based on BMI and metabolism, supervised by doctors and nutritionists.
Vashisht emphasizes that HealthifyRx is a companion program, not a drug-only solution. The goal is for users to build sustainable habits and eventually stop the injections.
This integrated approach aims to combine the benefits of GLP-1 drugs with long-term lifestyle changes to combat obesity effectively in India’s growing health market.
Related Topics:
Weight Loss Injections To Be Offered In Northern Ireland
